Lupin Pharmaceutical's Dabhasa unit, near Vadodara, received two Form 483s from the US health regulator, after thorough inspection from June 29 to July 6, the company said in a filing on the Bombay Stock Exchange (BSE).
Both theobservations are minor in nature and corrective and preventive actions were shown to the inspectors during theinspection.Lupin's BSE filing
Form 483 is used by the U.S. Food and Drug Administrator (U.S. FDA) to document and communicate concerns discovered during their inspections, according to the regulator's website.
On Thursday, the U.S. FDA closed the inspection carried out at Lupin's Goa plant in July 2015.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
